Literature DB >> 11071499

AIDS-related focal brain lesions in the era of highly active antiretroviral therapy.

A Ammassari1, A Cingolani, P Pezzotti, D A De Luca, R Murri, M L Giancola, L M Larocca, A Antinori.   

Abstract

OBJECTIVE: To compare the years since the introduction of highly active antiretroviral therapy (HAART) with the pre-HAART era for trends in the proportions of HIV-related focal brain lesion-causing disorders.
METHODS: A prospective, single-center study of all consecutive HIV-infected patients with a neurologic presentation and focal brain lesions observed between January 1991 and December 1998 was undertaken.
RESULTS: The major diagnoses in the 281 patients were toxoplasmic encephalitis (36.4%), primary CNS lymphoma (26.7%), progressive multifocal leukoencephalopathy (18.2%), and focal HIV encephalopathy (5.0%). During the HAART period, patients were less likely to be male, contracted HIV more often through heterosexual exposure, had fewer previous AIDS-defining events, received antiToxoplasma prophylaxis less frequently, had a CD4+ lymphocyte count 2.5 times higher, and had diagnosis based more often on PCR assays from CSF, reducing the need for brain biopsy and enhancing the likelihood of in vivo diagnosis. Using all patients hospitalized per year as reference population, the risk of focal brain lesions strongly increased during the pre-HAART period and declined significantly during the HAART years. In the HAART period a relevant decline of primary CNS lymphoma was found (OR for 1998, 0.25; p for trend = 0.03) and the effect of progressive calendar year was confirmed on multivariable analysis (OR, 0.52; 95% CI, 0.28 to 0.97). The frequency of toxoplasmic encephalitis decreased during the pre-HAART era and was stable afterwards. For progressive multifocal leukoencephalopathy, a slight increase was seen over time. Focal white matter lesions without enhancement or mass effect increased between 1991 and 1998.
CONCLUSIONS: During the HAART era, AIDS-related primary CNS lymphoma showed a strong decline, toxoplasmic encephalitis remained stable, and progressive multifocal leukoencephalopathy showed a slight increase. Focal white matter lesions without mass effect or contrast enhancement became the most frequently seen focal brain lesion. For differential diagnosis, PCR-based assays from CSF led to a shift from brain biopsy toward a minimally invasive approach with an augmented likelihood of in vivo diagnosis.

Entities:  

Mesh:

Year:  2000        PMID: 11071499     DOI: 10.1212/wnl.55.8.1194

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study.

Authors:  A De Luca; M L Giancola; A Ammassari; S Grisetti; A Cingolani; D Larussa; L Alba; R Murri; G Ippolito; R Cauda; A Monforte; A Antinori
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

3.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

4.  Hidden in plain view: emergence of progressive multifocal leukoencephalopathy after treatment of CNS toxoplasmosis.

Authors:  Sarah Gheuens; Sarah H Cheeseman; Igor J Koralnik
Journal:  Acta Neurol Belg       Date:  2011-09       Impact factor: 2.396

5.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

6.  White matter lesions in a young HIV-positive immunocompetent patient without cerebrovascular risk factors due to an ICA-thrombus.

Authors:  George Trendelenburg; Juri Katchanov; Florian Masuhr; Randof Klingebiel; Rolf Zschenderlein
Journal:  J Neurol       Date:  2005-07-18       Impact factor: 4.849

7.  Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).

Authors:  T R Kiderlen; O Liesenfeld; D Schürmann; T Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

Review 8.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

9.  Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples.

Authors:  Fabio A Colombo; José E Vidal; Augusto C Penalva de Oliveira; Adrián V Hernandez; Francisco Bonasser-Filho; Roberta S Nogueira; Roberto Focaccia; Vera Lucia Pereira-Chioccola
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

10.  Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Authors:  Navdeesh Sidhu; J Allen McCutchan
Journal:  J Neuroimmunol       Date:  2009-12-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.